Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARLS: pembrolizumab versus placebo after resection and standard adjuvant therapy for early-stage NSCLC
2015-000575-27Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jul 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab with Placebo (2 arms). Primary endpoint: Disease-free survival in the PD-L1 strong positive subgroup. Started Jul 2015; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-000575-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000575-27.